You are here

  • Home
  • Archive
  • Volume 47, Issue Suppl 1
  • B324 Erector spinae plane block for robot-assisted minimally invasive direct coronary artery bypass surgery: a double-blind, prospective randomized placebo-controlled trial

Article Text

Article menu

Download PDFPDF

Postoperative pain management
B324 Erector spinae plane block for robot-assisted minimally invasive direct coronary artery bypass surgery: a double-blind, prospective randomized placebo-controlled trial
Free
  1. DF Hoogma1,2,
  2. R van den Eynde1,
  3. W Oosterlinck3,2,
  4. L Al tmimi1,2,
  5. J Tournoy4,
  6. P Verbrugghe3,2,
  7. S Fieuws5,
  8. S Coppens1,2 and
  9. S Rex1,2
  1. 1University Hospitals Leuven, Department of Anesthesiology, Leuven, Belgium,
  2. 2University of Leuven, Biomedical Sciences Group, Department of Cardiovascular Sciences, Leuven, Belgium,
  3. 3University Hospitals of Leuven, Department of Cardiac Surgery, Leuven, Belgium,
  4. 4Geriatric Medicine, University Hospitals Leuven, Department of Public Health and Primary Care, Leuven, Belgium,
  5. 5University of Leuven, Biomedical Sciences Group, Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), Leuven, Belgium

Abstract

Background and Aims Thoracotomy for robot-assisted minimally invasive direct coronary artery bypass (RAMIDCAB) surgery may cause severe early postoperative pain.1The Erector Spinae Plane (ESP) block may be an effective and safe option for postoperative analgesia in RAMIDCAB surgery.2As randomized trials in this field are lacking,3we investigated ifin RAMIDCAB surgery, intermittent ESP block adjuvant to the standard multimodal analgesic regimen, compared to solely the latter, is effective in reducing postoperative pain.

Methods This single center, double-blind, prospective, randomized, placebo-controlled trial was approved by the Ethics Committee of the University Hospitals Leuven, Belgium (DH 11–2018 Version 008 26–10-2020 – EudraCT 2019–000596-16). The trial was supported by an ESRA Research Grant 2019. Between May 15th2019 and July 4th2021, 64 patients undergoing RAMIDCAB surgery were randomized to postoperatively receive an ESP catheter with either intermittent ropivacaine 0.5% (ropi-group) or normal saline 0.9% (placebo-group). Primary endpoint was postoperative 24h morphine consumption. Multiple secondary endpoints were evaluated up to 30-days postoperatively.

Results The median (IQR) 24h morphine consumption was not different between the ropi- and placebo-group: 67mg (35;84) vs 71mg (52;90), p=0.25. Mean numerical rating scale values for pain showed no significant difference between the groups (Figure 1). The number of morphine-boluses requested each hour by the patient and other secondary outcomes were comparable, figure 2 and table 1, respectively.

Abstract B324 Figure 1
Abstract B324 Figure 1
Abstract B324 Figure 2
Abstract B324 Figure 2
View this table:
Abstract B324 Table 1

Conclusions In the current study, adding an ESP-block to a standard multimodal analgesia regimen did not result in reduced morphine consumption after RAMIDCAB surgery.

http://dx.doi.org/10.1136/rapm-2022-ESRA.400

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.